Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Sigma-Tau sign agreement

Pfizer and Sigma-Tau sign agreement

10th December 2008

Pfizer and Sigma-Tau have entered into a license and supply agreement.

The deal will see the marketing of Eurartesim, a novel fixed dose artemisinim-based combination therapy.

A phase III product candidate, the drug is for the treatment of uncomplicated Plasmodium falciparum malaria in adults and children and reduces the potential for re-infection.

The product is expected to be filed for registration with the European Medicines Agency and has already been granted orphan drug status by the European regulatory authorities.

Jean-Michel Halfron, president and general manager of emerging markets at Pfizer, said: “Pfizer is excited about our collaboration with Sigma-Tau.”

“The effective treatment of malaria, a preventable and treatable disease, is an essential need for patients in many countries.”

He went on to say the agreement “supports Pfizer’s vision to serve the needs of patients”.

Malaria is one of the leading causes of infant mortality – the World Health Organisation estimated 881,000 worldwide deaths in 2006 were due to the disease.

Founded in 1849, Pfizer is based in New York, US, with six research and development locations – including one in Sandwich, Kent.

In 2007, the company’s revenues were $48.4 billion (32.3 billion pounds).

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.